- Gilead Sciences Inc GILD and Arcus Biosciences Inc RCUS announced results from the fourth interim analysis of the ARC-7 Phase 2 study for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.
- The study evaluates the combinations of domvanalimab + zimberelimab (doublet) and domvanalimab + zimberelimab + etrumadenant (triplet) versus zimberelimab monotherapy.
- Related: Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures.
- The doublet and triplet combinations demonstrated clinically meaningful improvements in median progression-free survival (PFS) and six-month landmark PFS rates compared to zimberelimab monotherapy, with a 45% reduction in risk of disease progression or death for the doublet and 35% for the triplet.
- Each of the domvanalimab-containing study arms also demonstrated clinically meaningful improvements in objective response rate (ORR) compared to zimberelimab monotherapy. Confirmed ORR was 27%, 41%, and 40% for the zimberelimab monotherapy arm and the domvanalimab-doublet and -triplet arms, respectively.
- While the triplet arm did not show an improvement over the doublet arm, it reinforces the results observed in the doublet arm.
- The study will continue to monitor PFS and overall survival for the triplet arm as these data mature.
- No unexpected safety signals were observed across the three study arms. The domvanalimab-containing study arms were generally well tolerated and showed an overall safety profile.
- Price Action: GILD shares are down 5.25% at $81.89, and RCUS shares are down 31% at $21.25 on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.